Research on osteosarcoma treatment has revealed that DDRGK domain-containing protein 1 (DDRGK1) inhibits the ubiquitin-proteasome-mediated degradation of NRF2 by competitively binding to Keap1. The gene discussed is DDRGK1; the disease is osteosarcoma.